DOI: 10.1111/imj.70464 ISSN: 1444-0903
Medication discontinuation in the era of elexacaftor/tezacaftor/ivacaftor: an Australian survey and qualitative interview
Matthew Corbett, Bandana Saini, Anna Dunn, Simone Visser, Helen Jo, Veronica Yozghatlian, Jody Bell, Sheila SivamABSTRACT
Chloride channel potentiator and corrector elexacaftor/tezacaftor/ivacaftor (ETI) has reduced the burden of disease in people with cystic fibrosis (PwCF) and led to some patients ceasing high‐burden treatment regimens. This study was a prospective survey and qualitative interview that evaluated medications PwCF had ceased after ETI. It demonstrated that a majority of PwCF have ceased medications, which prompts further research to rationalise medication regimens for PwCF.